Federal Register / Vol. 72, No.
96 / Friday, May 18, 2007 / Notices 28073
DEA has considered the factors in 21
U.S.C. 823(a) and determined that the
registration of Chattem Chemicals, Inc.
to manufacture the listed basic classes
of controlled substances is consistent
with the public interest at this time.
DEA has investigated Chattem
Chemicals, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9644 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 28, 2006, Cody
Laboratories, Inc., 601 Yellowstone
Avenue, Cody, Wyoming 82414, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule I and II:
Drug
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Cocaine (9041) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Meperidine (9230) ........................
Oxymorphone (9652) ...................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
pwalker on PROD1PC71 with NOTICES
The company plans on manufacturing
the listed controlled substance in bulk
for sale to its customers.
Any other such applicant, and any
person who is presently registered with
VerDate Aug<31>2005 17:06 May 17, 2007 Jkt 211001
DEA to bulk manufacture such a
substance, may file comments or
objections to the issuance of the
proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register
Representative(ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative(ODL), 2401 Jefferson
Davis Highway, Alexandria, Virginia
22301; and must be filed no later than
July 17, 2007.
Dated: May 10, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9608 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated February 5, 2007 and
published in the Federal Register on
February 12, 2007, (72 FR 6578–6579),
Fisher Clinical Services Inc., 7554
Schantz Road, Allentown, Pennsylvania
18106, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
Noroxymorphone (9668), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance for analytical
Schedule research and clinical trials.
No comments or objections have been
I received. DEA has considered the
II
factors in 21 U.S.C. 823(a) and 952(a)
II
II and determined that the registration of
II Fisher Clinical Services Inc. to import
II the basic class of controlled substance is
II consistent with the public interest and
II with United States obligations under
II international treaties, conventions, or
II protocols in effect on May 1, 1971, at
II
II this time. DEA has investigated Fisher
Clinical Services Inc. to ensure that the
II
II company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 E:\FR\FM\18MYN1.SGM
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9610 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated November 21, 2006
and published in the Federal Register
on December 1, 2006, (71 FR 69590),
Formulation Technologies LLC, 11400
Burnet Road, Suite 4010, Austin, Texas
78758, made application to the Drug
Enforcement Administration (DEA) to
be registered as an importer of Fentanyl
(9801), a basic class of controlled
substance listed in schedule II.
The company plans to import the
listed controlled substance for clinical
trials, research, analytical purposes and
distribution to its customers.
One objection was received; however,
it has subsequently been withdrawn.
DEA has considered the factors in 21
U.S.C. 823(a) and 952(a) and determined
that the registration of Formulation
Technologies LLC to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated
Formulation Technologies LLC to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
18MYN1
 28074 Federal Register / Vol. 72, No. 96 / Friday, May 18, 2007 / Notices
Dated: May 10, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9606 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated December 14, 2006,
and published in the Federal Register
on December 22, 2006, (71 FR 77065–
77066), Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of 14–
Hydroxymorphinone (9654), a basic
class of controlled substance listed in
schedule II.
The company plans to manufacture
the listed controlled substances in bulk
as an intermediate for use in the
production of another controlled
substance.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc to manufacture the
listed basic class of controlled substance
is consistent with the public interest at
this time. DEA has investigated Johnson
Matthey Inc to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
pwalker on PROD1PC71 with NOTICES
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9617 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005 17:06 May 17, 2007 Jkt 211001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated November 2, 2006,
and published in the Federal Register
on November 8, 2006, (71 FR 65544),
Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
II:
Drug
Nabilone (7379) ............................
Noroxymorphone (9668) ..............
The company plans to manufacture
the listed controlled substances in bulk
for sales to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc. to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Johnson Matthey Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9629 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated December 14, 2006,
and published in the Federal Register
on December 22, 2006, (71 FR 77065),
PO 00000 Frm 00056 Fmt 4703 Sfmt 4703
Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Remifentanil (9739), a
basic class of controlled substance listed
in schedule II.
The company plans on producing this
item for sale to its customers, who are
final dosage manufacturers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc to manufacture the
listed basic class of controlled substance
is consistent with the public interest at
Schedule this time. DEA has investigated Johnson
Matthey Inc to ensure that the
II company’s registration is consistent
II with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: May 9, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9634 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated December 14, 2006,
and published in the Federal Register
on December 22, 2006, (71 FR 77065–
77066), Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of 14–
Hydroxymorphinone (9654), a basic
class of controlled substance listed in
schedule II.
The company plans to manufacture
the listed controlled substances in bulk
as an intermediate for use in the
production of another controlled
substance.
E:\FR\FM\18MYN1.SGM 18MYN1